Shares of Zydus Lifesciences rose 1.19% to Rs 1,007.95 in Wednesday's session, witnessing a surge in volume. The stock is among the top gainers on the Nifty Next 50 index.
The stock's upward movement was observed on the NSE as of 3:22 pm.
Financial Overview:
Zydus Lifesciences has demonstrated substantial financial performance, as highlighted by both quarterly and annual results. The consolidated revenue for the quarter-ending June 2025 stood at Rs 6,573.70 Crore, compared to Rs 6,207.50 Crore in June 2024. The net profit for the same period was Rs 1,486.60 Crore, up from Rs 1,463.60 Crore in the previous year.
The annual consolidated revenue for the year-ending March 2025 reached Rs 23,241.50 Crore, a significant increase from Rs 19,547.40 Crore in March 2024. The net profit also saw a considerable rise, from Rs 3,831.40 Crore in 2024 to Rs 4,614.80 Crore in 2025.
Income Statement:
The following table presents the Consolidated Income Statement of Zydus Lifesciences:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 23,241 Crore | Rs 19,547 Crore | Rs 17,237 Crore | Rs 15,265 Crore | Rs 14,403 Crore |
| Other Income | Rs 269 Crore | Rs 284 Crore | Rs 186 Crore | Rs 224 Crore | Rs 45 Crore |
| Total Income | Rs 23,511 Crore | Rs 19,831 Crore | Rs 17,424 Crore | Rs 15,489 Crore | Rs 14,449 Crore |
| Total Expenditure | Rs 17,318 Crore | Rs 14,941 Crore | Rs 14,704 Crore | Rs 12,524 Crore | Rs 11,891 Crore |
| EBIT | Rs 6,192 Crore | Rs 4,890 Crore | Rs 2,719 Crore | Rs 2,965 Crore | Rs 2,558 Crore |
| Interest | Rs 165 Crore | Rs 81 Crore | Rs 129 Crore | Rs 127 Crore | Rs 158 Crore |
| Tax | Rs 1,411 Crore | Rs 977 Crore | Rs 587 Crore | Rs 511 Crore | Rs 193 Crore |
| Net Profit | Rs 4,614 Crore | Rs 3,831 Crore | Rs 2,001 Crore | Rs 2,326 Crore | Rs 2,205 Crore |
Quarterly Income Statement:
The following table presents the Consolidated Quarterly Income Statement of Zydus Lifesciences:
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | Rs 6,573 Crore | Rs 6,527 Crore | Rs 5,269 Crore | Rs 5,237 Crore | Rs 6,207 Crore |
| Other Income | Rs 154 Crore | Rs 80 Crore | Rs 57 Crore | Rs 68 Crore | Rs 63 Crore |
| Total Income | Rs 6,728 Crore | Rs 6,608 Crore | Rs 5,326 Crore | Rs 5,305 Crore | Rs 6,270 Crore |
| Total Expenditure | Rs 4,723 Crore | Rs 4,859 Crore | Rs 4,110 Crore | Rs 4,009 Crore | Rs 4,338 Crore |
| EBIT | Rs 2,005 Crore | Rs 1,748 Crore | Rs 1,215 Crore | Rs 1,296 Crore | Rs 1,931 Crore |
| Interest | Rs 84 Crore | Rs 76 Crore | Rs 32 Crore | Rs 25 Crore | Rs 32 Crore |
| Tax | Rs 434 Crore | Rs 423 Crore | Rs 179 Crore | Rs 373 Crore | Rs 436 Crore |
| Net Profit | Rs 1,486 Crore | Rs 1,248 Crore | Rs 1,004 Crore | Rs 898 Crore | Rs 1,463 Crore |
The cash flow statement provides insights into the company's liquidity and cash management. The cash flow from operating activities for the year-ending March 2025 was Rs 6,776 Crore, compared to Rs 3,227 Crore in the previous year. The net cash flow stood at Rs 413 Crore, a notable turnaround from a decrease of Rs 74 Crore in the previous year.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 6,776 Crore | Rs 3,227 Crore | Rs 2,688 Crore | Rs 2,104 Crore | Rs 3,293 Crore |
| Investing Activities | Rs -8,372 Crore | Rs -1,475 Crore | Rs 1,171 Crore | Rs 1,154 Crore | Rs -724 Crore |
| Financing Activities | Rs 2,014 Crore | Rs -1,810 Crore | Rs -4,400 Crore | Rs -868 Crore | Rs -2,547 Crore |
| Others | Rs -4 Crore | Rs -17 Crore | Rs 6 Crore | Rs -17 Crore | Rs -112 Crore |
| Net Cash Flow | Rs 413 Crore | Rs -74 Crore | Rs -533 Crore | Rs 2,372 Crore | Rs -90 Crore |
The balance sheet reflects the company's financial stability and asset distribution. As of March 2025, the total assets amounted to Rs 37,201 Crore, compared to Rs 29,280 Crore in the previous year. The total liabilities increased from Rs 29,280 Crore in 2024 to Rs 37,201 Crore in 2025.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 100 Crore | Rs 100 Crore | Rs 101 Crore | Rs 102 Crore | Rs 102 Crore |
| Reserves & Surplus | Rs 23,852 Crore | Rs 19,728 Crore | Rs 17,414 Crore | Rs 16,897 Crore | Rs 12,889 Crore |
| Current Liabilities | Rs 9,041 Crore | Rs 5,341 Crore | Rs 5,530 Crore | Rs 7,839 Crore | Rs 7,861 Crore |
| Other Liabilities | Rs 4,206 Crore | Rs 4,109 Crore | Rs 2,709 Crore | Rs 2,956 Crore | Rs 3,031 Crore |
| Total Liabilities | Rs 37,201 Crore | Rs 29,280 Crore | Rs 25,756 Crore | Rs 27,795 Crore | Rs 23,884 Crore |
| Fixed Assets | Rs 10,583 Crore | Rs 9,525 Crore | Rs 7,917 Crore | Rs 7,549 Crore | Rs 7,569 Crore |
| Current Assets | Rs 17,046 Crore | Rs 11,501 Crore | Rs 10,016 Crore | Rs 12,261 Crore | Rs 8,716 Crore |
| Other Assets | Rs 9,572 Crore | Rs 8,253 Crore | Rs 7,822 Crore | Rs 7,984 Crore | Rs 7,599 Crore |
| Total Assets | Rs 37,201 Crore | Rs 29,280 Crore | Rs 25,756 Crore | Rs 27,795 Crore | Rs 23,884 Crore |
| Contingent Liabilities | Rs 1,428 Crore | Rs 1,277 Crore | Rs 1,315 Crore | Rs 1,210 Crore | Rs 1,295 Crore |
Zydus Lifesciences exhibits strong financial health, with a basic EPS of Rs 44.97 and a diluted EPS of Rs 44.97 for March 2025. The company's book value per share is Rs 238.10. The company’s debt to equity ratio is 0.13 as of year ending March 2025.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 44.97 | 38.14 | 19.30 | 43.83 | 20.84 |
| Diluted Eps (Rs.) | 44.97 | 38.14 | 19.30 | 43.83 | 20.84 |
| Book Value [Excl. Reval Reserve]/Share (Rs.) | 238.10 | 219.70 | 194.55 | 186.07 | 145.80 |
| Dividend/Share (Rs.) | 11.00 | 3.00 | 6.00 | 2.50 | 3.50 |
| Face Value | 1 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 31.52 | 28.99 | 23.47 | 23.35 | 23.83 |
| Operating Margin (%) | 27.58 | 25.08 | 19.28 | 18.68 | 19.18 |
| Net Profit Margin (%) | 19.85 | 19.71 | 11.58 | 29.95 | 14.84 |
| Return on Networth / Equity (%) | 18.89 | 19.46 | 11.19 | 26.39 | 16.42 |
| ROCE (%) | 22.77 | 20.48 | 16.43 | 14.29 | 17.24 |
| Return On Assets (%) | 12.16 | 13.18 | 7.61 | 16.14 | 8.93 |
| Current Ratio (X) | 1.89 | 2.15 | 1.81 | 1.56 | 1.11 |
| Quick Ratio (X) | 1.45 | 1.51 | 1.19 | 1.09 | 0.70 |
| Debt to Equity (x) | 0.13 | 0.04 | 0.07 | 0.25 | 0.35 |
| Interest Coverage Ratios (X) | 44.17 | 69.81 | 31.15 | 28.07 | 21.62 |
| Asset Turnover Ratio (%) | 0.70 | 0.71 | 0.64 | 0.38 | 0.37 |
| Inventory Turnover Ratio (X) | 6.29 | 1.34 | 1.16 | 1.02 | 1.03 |
| 3 Yr CAGR Sales (%) | 23.39 | 16.50 | 9.97 | 7.68 | 9.99 |
| 3 Yr CAGR Net Profit (%) | 40.84 | 31.80 | 30.49 | 12.08 | 11.74 |
| P/E (x) | 19.71 | 26.41 | 25.47 | 7.95 | 21.16 |
| P/B (x) | 3.72 | 5.10 | 2.84 | 2.10 | 3.47 |
| EV/EBITDA (x) | 12.52 | 18.18 | 12.97 | 11.46 | 14.79 |
| P/S (x) | 3.83 | 5.17 | 2.89 | 2.34 | 3.13 |
Zydus Lifesciences announced a final dividend of Rs 11 per share (1100%) on May 20, 2025, with an effective date of July 25, 2025. Earlier dividends include Rs 3 per share in 2024, Rs 6 per share in 2023, Rs 2.50 per share in 2022, and Rs 3.50 per share in 2021.
The company has also announced bonus issues in the past. One bonus was announced on February 25, 2010, with an existing ratio of 2:1 and ex-bonus date was April 05, 2010. Another bonus was announced on April 28, 2006, with a bonus ratio of 1:1 and ex-bonus date was August 30, 2006.
A stock split was announced on August 12, 2015, with an ex-split date of October 6, 2015, changing the face value from Rs 5 to Rs 1.
Press releases from Zydus Lifesciences include updates on regulatory submissions and approvals, and research and development advancements.
With the stock's last traded price at Rs 1,007.95, Zydus Lifesciences has seen a positive momentum during today's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
